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Summary
Chronic synovial inflammation in rheumatoid arthritis
(RA) leads to progressive damage to articular cartilage and
bone, ultimately resulting in disability. Therefore, control
of the articular inflammation is of great importance to pre-
vent joint damage. A variety of disease-modifying anti-
rheumatic drugs (DMARDs) are available for RA patients.
Conventional synthetic DMARDs, and in particular bio-
logical DMARDs, have been shown to effectively inhibit
joint destruction in RA. Longitudinal assessments of radio-
graphic changes in patients with RA in clinical trials and
in large patient registries have clearly shown that delays in
the initiation of DMARD therapy results in significantly in-
creased progression of joint damage. Patients started early
on DMARDs had significantly lower radiographic damage
progression than patients initiating DMARD treatment
later. These effects were maintained for several years, sug-
gesting that early in the development of RA a therapeutic
window of opportunity exists in which DMARD therapy
decisively influences the long-term prognosis. Therefore,
to improve the clinical outcome of RA, our efforts should
be directed towards diagnosing RA earlier and introducing
DMARD therapy immediately after the diagnosis has been
made.
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Background
Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease primarily affecting the joints. Chronic synovitis in RA
leads to progressive joint damage in the great majority of
patients. Inflammatory cells in the synovium produce cy-
tokines that activate proliferation of synovial fibroblasts
and macrophages. The resulting hyperplastic synovium is
the source of proteases that degrade articular cartilage and
of osteoclast activating factors. Activated osteoclasts lead
to bone erosions, typically at the junction of bone and car-
tilage. Whereas erosions are usually not visible on conven-
tional radiographs in the early stages of the disease, clin-
ical studies using magnetic resonance imaging (MRI) have
clearly demonstrated that bone erosions occur as early as 4
months after the first symptoms of joint inflammation [1].
As bone and cartilage damage is irreversible, early thera-
peutic intervention is of paramount importance for the pro-
gnosis of patients.
Major advances have been made in controlling joint dam-
age with the introduction of the so-called disease-modify-
ing antirheumatic drugs (DMARDs). Evidence from clin-
ical trials has shown that treatment of RA with DMARDs
results in less radiographically assessed damage and a bet-
ter long-term prognosis [2]. In particular, it has been shown
that early initiation of DMARD therapy has a long-term
beneficial effect on joint destruction that extends far bey-
ond the initial treatment period. This has led to a paradigm
of RA including a therapeutic “window of opportunity” in
early disease [3, 4].
In this review the mechanisms of joint damage and avail-
able outcome measures will be discussed. Then the evid-
ence for early therapeutic intervention will be summarised
with special consideration of the data from the Swiss Clin-
ical Quality Management (SCQM) patient cohort.
Mechanisms of joint damage
Synovial hyperplasia is the origin of joint damage. Mono-
cytes are recruited into the synovium and locally differenti-
ate into macrophages. Proliferation of synovial fibroblasts
in the synovial membrane lining is driven by cytokines pro-
duced by leukocytes in the synovium and local production
by the activated synovial cells themselves. Fibroblast-like
synoviocytes of patients with RA typically display an ac-
tivated phenotype, characterised by resistance to apoptosis,
loss of contact inhibition and the production of proinflam-
matory cytokines, contributing to sustained synovial hyper-
trophy. In addition, activated fibroblast-like synoviocytes
are a source of matrix-degrading enzymes [5, 6]. Activity
of matrix metalloproteinases, together with increased chon-
drocyte apoptosis caused by inflammatory cytokines, res-
ults in destruction of cartilage and, consequently, impair-
ment of proper joint function.
A hallmark of RA is the formation of bone erosions, typ-
ically at the junction of cartilage and bone. Osteoclast dif-
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ferentiation is under the control of cytokines. Receptor ac-
tivator of nuclear factor kappa-B ligand (RANKL) and
granulocyte-macrophage colony-stimulating factor (GM-
CSF) induce osteoclast differentiation, which is further
supported by inflammatory cytokines abundantly present in
the inflamed synovium, such as tumour necrosis factor-al-
pha (TNF-α), interleukin-1 (IL-1) and interleukin-6 (IL-6)
[7]. Erosions can lead to significant loss of articular bone.
Even in patients with sufficient control of inflammatory
activity, repair of bone erosions does not occur. It is, there-
fore, of great importance to intervene before significant
damage has occurred.
How can joint damage be measured in
rheumatoid arthritis?
Imaging methods in the assessment of joint damage
Assessment of structural joint damage is an important part
of disease monitoring in RA. Classically, X-ray has been
used for this purpose. With conventional radiography bone
erosions and periarticular osteopenia can be detected, as
well as joint-space narrowing, which is the result of car-
tilage damage. RA typically involves the small joints of
the hands and feet. Radiography allows a rapid, cost-effect-
ive and reproducible assessment of these joints. The pres-
ence of typical erosions on radiographs is highly specific
for RA in patients with established, long-standing disease
[8]. In the early stages of disease, the sensitivity of conven-
tional radiography is much lower, however, with specificity
remaining high [9]. Erosions are detected by convention-
al radiography in only 6%–40% of patients with RA at 6
months of disease duration [10]. Therefore the usefulness
of conventional radiography for the early diagnosis of RA
is limited. However, conventional radiography is still the
method of choice for monitoring joint damage over time in
patients with established disease.
Magnetic resonance imaging (MRI) has the advantage of
allowing a three-dimensional assessment of the joints, in-
cluding not only the bone, but also the cartilage and the
soft tissues. The sensitivity of MRI for the detection of
bone erosions in RA is higher than that of conventional ra-
diography [11, 12] and is comparable to computed tomo-
graphy, which is considered the gold standard for detection
of erosions in RA [13].
In addition to the detection of bone erosions and cartilage
degradation, MRI allows assessment of synovial inflamma-
tion and, thereby, the activity of the disease [14]. Thicken-
ing of the synovial membrane, increased synovial volume
and enhancement of synovial tissue after administration of
gadolinium are measures of the activity of synovitis [15].
MRI findings of synovitis have been shown to correlate
well with macroscopic findings on arthroscopy and clinic-
al disease activity [16]. Another feature seen exclusively in
MRI is bone oedema. Bone oedema is nonspecific, as it can
occur in traumatic and in degenerative and inflammatory
bone disorders. Bone marrow oedema corresponds to cel-
lular infiltrates in the subchondral bone [17]. Bone marrow
oedema is highly prevalent in the early stages of RA and
predicts erosive disease [18]. Owing to its superior sensit-
ivity to bone damage in early RA, MRI is increasingly used
in clinical studies for assessment of destructive changes.
Ultrasound has attracted a great deal of interest as a tool for
diagnosis and for monitoring joint damage in RA and other
rheumatic diseases. Much like MRI, it allows the detection
of synovial thickening and synovial effusion. In addition,
power Doppler provides a quantification of the vascularisa-
tion of the synovial tissue [19]. Ultrasonography is clearly
more sensitive for the detection of bone erosions than con-
ventional radiography in early RA [20]. Good sensitivity
and specificity for erosions in metacarpophalangeal (MCP)
joints has been documented for sonography in comparison
with MRI [21]. However, its use is limited to joints easily
accessible to examination, such as the hand joints. Assess-
ment of cartilage thickness is possible with ultrasound. It
has been shown that cartilage thickness measurements with
sonography correlate with joint-space narrowing seen with
conventional radiography in finger joints [22]. Ultrasound
is increasingly used in clinical practice because of its avail-
ability at the bed-side and its relative inexpensiveness com-
pared with MRI. Apart from being a powerful tool to de-
tect synovitis in early stages of RA, power Doppler signal
in the joints of patients with early RA has been shown to
be predictive for radiographic progression in a longitudin-
al observational study [23]. Moreover, in DMARD-treated
patients in clinical remission, power Doppler signal was
a predictor of radiographic progression and of disease re-
lapse [24, 25]. Thus, joint ultrasound may help to guide
therapeutic decisions.
However, a variety of different scoring systems have been
used in clinical studies. So far, there are no consensus
definitions for the use of sonography in routine clinical
practice or in clinical studies.
Imaging methods for the assessment of joint damage
used in clinical studies
Several semiquantitative scoring methods have been de-
veloped to assess progressive joint damage over time on
conventional radiographs. Available damage scores assess
the level of damage at individual joints, which are then
pooled to form a global damage score. Radiographic dam-
age scores are considered the gold standard for assessment
of disease progression in RA [26]. In fact, radiographic out-
comes can be blinded for objective scoring; damage scores
are not much influenced by short-term variations in dis-
ease activity, and they provide a cumulative measure of
disease activity over time. Established scoring methods of
radiographic joint damage include the Sharp scoring meth-
od (and various modifications of it), the Larsen scoring
method, or the Ratingen scoring method, which is used by
the Swiss RA cohort SCQM. These methods differ in the
joints assessed or the way joint-space narrowing (measure
of cartilage damage) is incorporated. Some randomised tri-
als have added MRI scores or ultrasound scores to conven-
tional radiographic damage scores, neither MRI scores nor
ultrasound scores are currently accepted by the regulatory
authorities as an outcome measure for joint damage.
Review article: Current opinion Swiss Med Wkly. 2013;143:w13865
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 2 of 7
Current principles of rheumatoid
arthritis treatment
Once the diagnosis of RA is made, all patients should re-
ceive therapy with DMARDs. DMARDs are defined as
drugs able to inhibit or delay the destructive changes oc-
curring in joints of patients with RA. Although glucocor-
ticosteroids also have some disease-modifying effects, they
are usually not included in this group, as their side effects
prevent them from being used as monotherapy for long-
term control of RA. There are a variety of DMARDs with
proven efficacy in RA (table 1). They are divided in con-
ventional DMARDs, small molecules with immuno-sup-
pressive or -modulatory function, and the so-called biolo-
gical DMARDs. The latter are drugs which are biotechno-
logically generated and specifically target key pathways of
autoimmunity and inflammation. As these drugs are usu-
ally proteins, antibodies or receptor fusion proteins, they
have to be administered parenterally. The increasing num-
ber of DMARDs licensed for treatment of RA has presen-
ted rheumatologists with the difficulty of choosing the ap-
propriate drug or combination of drugs for an individual
RA patient.
A multitude of clinical studies have been performed in re-
cent years permitting guidelines for the use of DMARDs
in RA to be worked out. Recently, new guidelines by the
European League against Rheumatism (EULAR) have
been published [2]. To summarise these briefly, patients
with RA should receive methotrexate as first-line therapy,
in the absence of contraindications. If methotrexate is not
tolerated or insufficiently effective, therapy can either be
switched to another synthetic DMARD or another
DMARD can be added to methotrexate. Biological therapy
in combination with methotrexate is recommended in pa-
tients with insufficient response to methotrexate and risk
factors for progressive erosive disease. Clinical trials have
demonstrated that the addition of a biologic in these pa-
tients results in a significant reduction of clinical disease
activity and radiographic progression [27]. Importantly, a
reduction in radiographic progression on biologics was ob-
served even in patients with residual inflammatory activity,
suggesting a disconnect between synovitis and erosive pro-
cesses [28]. Therefore, in patients at high risk of radio-
graphic joint damage, biologic drugs are indicated when
first-line therapy with methotrexate has failed.
Current guidelines suggest that the treatment goal should
be remission in patients with early disease. To monitor the
effects of therapy on disease activity, rheumatologists use
disease activity measures, such as the disease activity score
based on 28 joints (DAS28), which can be easily performed
during a visit to the office [29]. To achieve the ambitious
goal of remission, early initiation of therapy is of great
importance. Although this has been generally recognised,
many patients with RA are not treated with DMARDs
early in their disease. In the Swiss RA cohort the delay
between symptom onset and the first antirheumatic treat-
ment was 10 months, and a recent European study showed
that the median time from symptom onset to assessment by
a rheumatologist was 24 weeks [30]. This study suggests
that in the majority of patients, DMARD therapy is started
with a significant delay.
In the following section the evidence for a benefit of early
start of DMARD treatment will be discussed.
Evidence for a long-term effect of
early therapy on joint damage in
rheumatoid arthritis
Several studies have demonstrated that early antirheumatic
intervention in RA is particularly effective in preventing
structural joint damage, with large effect sizes compared
with similar interventions later in the disease course.
Whereas the increased effect of early intervention can eas-
ily be explained by patient selection, some studies have fur-
ther suggested that early initiation of DMARD treatment
may have a long-term benefit [31–33]. Based on these
findings, a therapeutic window of opportunity paradigm in
early RA has emerged, a long-lasting effect from a lim-
ited, initial intervention that would permanently amend the
course of joint destruction towards milder disease.
A meta-analysis of 12 published studies confirmed that the
long-term rates of radiographic damage are significantly
lower in patients starting DMARD therapy early as com-
pared with patients starting the same therapy later [34]. A
delay of only 9 months in initiating antirheumatic treatment
resulted in significantly increased subsequent joint damage
over the next years. Although the benefit of early treatment
has been confirmed in several other recent extension stud-
ies, a recent analysis of an early intervention study with
conventional DMARDs has examined the rate of radio-
graphic damage progression between 5 and 11 years after
the initial intervention and could no longer show a differ-
ence in the rates of radiographic progression between the
two treatment arms, which was present in the first 5 years
Table 1: Conventional disease-modifying antirheumatic drugs (DMARDs) and biologics licensed in Switzerland for the treatment of rheumatoid arthritis.
Conventional DMARDs Biologics
Methotrexate Tumour necrosis factor inhibitors:
Adalimumab
Certolizumab Pegol
Etanercept
Golimumab
Infliximab
Leflunomide Abatacept (T-cell costimulation blockade)
Sulfasalazine Tocilizumab (anti-interleukin-6 receptor antibody)
Hydroxychloroquine Rituximab (B-cell depleting antibody)
Less commonly used DMARDs:
Gold
Azathioprine
Ciclosporin
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[35]. Although this suggests that the benefit of early treat-
ment may not persist for more than 5 years, the differences
in absolute radiographic scores between the treatment arms
reached at 5 years were maintained in the follow-up period
up to 11 years. Another meta-analysis examined the preval-
ence of drug-free remission and found that symptom dur-
ation before DMARD treatment initiation was independ-
ently associated with remission, suggesting the existence
of a “therapeutic window of opportunity” in early disease
[36]. Finally, it is well established that RA has become a
less severe disease over recent decades, which might be ex-
plained by more effective therapies, but this trend started
long before the current biological treatments, suggesting
that other factors play a role in improved disease outcomes,
such as a change in the RA treatment paradigm with early
aggressive therapy [37].
Considering the paucity of definitive randomised trials es-
tablishing the notion of a therapeutic window of opportun-
ity in early RA, we studied the effects of early DMARD
therapy on the long-term radiographic progression of RA
using data from the Swiss Clinical Quality Management
(SCQM) cohort of patients with RA [38]. This cohort of-
fers the advantage of including longitudinal radiographic
assessments.
Patients enrolled in the SCQM-RA, treated with DMARDs
within the first 5 years of symptom onset and for whom
serial radiographs were available were included in the ana-
lysis [39]. Patients who started a biological agent as first
therapy were excluded as we considered these patients to
be unrepresentative of the overall population of RA pa-
tients.
Figure 1
Progression of joint erosion score (Ratingen) over time in patients
treated early vs patients treated late with disease-modifying
antirheumatic drugs (DMARDs). Mean erosion (ERO) scores (±
SEM) are shown as percentages of maximum damage score as a
function of time since symptom onset. Regression analysis with
adjustment for potential confounders of radiographic progression
revealed a significant difference in the slopes of radiographic
damage progression.
Reproduced from: Kyburz D, Gabay C, Michel BA, Finckh A. The
long-term impact of early treatment of rheumatoid arthritis on
radiographic progression: a population-based cohort study.
Rheumatology (Oxford). 2011;50(6):1106–10, by permission of the
British Society of Rheumatology.
The primary outcome of the study was radiographic disease
progression. The change in radiographic joint damage (Rat-
ingen Score) compared with baseline was determined for
all patients. The variable of interest was the latency
between the first occurrence of symptoms and the initiation
of DMARD therapy. Symptom onset rather than time of
diagnosis was chosen as this is a better reflection of the
period of time the patients had active disease before treat-
ment was started, and circumvents the necessity to control
for a delay in diagnosis of the disease. The patients were
dichotomised into two groups according to the delay in
DMARD initiation. In the “early group”, patients initiated
DMARD therapy within 1 year after onset of symptoms.
Patients starting DMARD therapy between 1 and 5 years
after symptom onset constituted the “late group”.
A total of 970 patients were included in the analysis. Of
these, 368 patients were in the early group with a median
time to DMARD treatment initiation of 6 months. The 602
patients in the late group had a median time of 2.3 years
to DMARD initiation. Baseline clinical criteria were not
different with the exception of significantly higher disease
activity in the early group. In accordance with the high-
er disease activity, the baseline rate of radiographic pro-
gression, calculated by dividing the baseline radiographic
scores by the symptom duration, was significantly higher
in the early group. More than 80% of the patients in both
groups received methotrexate as a first DMARD.
The comparison of the rate of damage progression in the
groups revealed that the subsequent progression of radio-
graphic joint damage was lower in the early DMARD treat-
ment group, although the baseline radiographic progression
rate was higher in this group (fig. 1). When the result was
adjusted for potential confounding factors such as clinic-
al disease activity at baseline, cotherapy with DMARDs or
glucocorticoids, or rheumatoid factor positivity, there was
still significantly lower damage progression in the patients
treated early with DMARD than with delayed DMARD
treatment. Notably, the differences in progression rates per-
sisted for the follow-up time of 4 years. Four years after
symptom onset, mean radiographic progression was still
higher in the late DMARD group than in the early group.
This result was not dependent on the DMARD, as it was
seen in patients treated with methotrexate as well as in pa-
tients on other conventional DMARDs. The benefit of early
DMARD therapy was especially pronounced in the patients
with a high radiographic progression at baseline.
Importantly, the reduced rate of radiographic progression
found in the patients with early DMARD treatment trans-
lated into significantly lower absolute damage as assessed
with the Ratingen score at 5 years. This result clearly
shows that early initiation of DMARD treatment results in
a long-lasting benefit, with reduced damage over several
years. Thus, this large study of the SCQM-RA cohort
strongly supports the concept of a window of opportunity
in RA, suggested previously in several smaller studies.
The definition of early RA varied in the different studies.
In the SCQM study, a symptom duration of less than 1 year
was used to define early RA, with a median symptom dur-
ation of 6 months. Other studies have used more stringent
criteria with symptom durations of 6 months or less. The
majority of these studies have shown a beneficial effect
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of early therapy [36]. Notably, even when patients treated
within 3 months were compared with patients treated at
more than 3 months after symptom onset significantly
lower radiographic progression could be demonstrated [32,
40, 41]. These results suggest that the therapeutic window
of opportunity may be as short as a few months. The fact
that a delay in therapy even of only 3 months may lead
to significantly increased joint damage over the following
several years is a reminder of our responsibility to initiate
DMARD therapy as soon as patients are diagnosed with
RA, with the aim of achieving a remission of disease.
Conclusion
Improved understanding of the pathogenesis of RA has led
to important advances in the treatment of this debilitating
disease. Nowadays, an increasing number of potent anti-
rheumatic agents are available, allowing disease control in
the majority of the patients. As joint damage in RA cannot
be reversed with currently available treatments, antirheum-
atic therapy should be started as early as possible to pre-
vent permanent structural damage and long-term functional
impairment. Data from clinical trials, as well as from large
patient registries such as the SCQM, have demonstrated
that delays in the initiation of DMARD therapy leads to
significantly increased progression of joint damage, not
only in the short run, but also during at least 5 years of
follow-up. Furthermore, good clinical outcomes become
rarer in patients in whom effective therapy is delayed early
in the disease course. These data emphasise that a “window
of opportunity” exists in early RA, a period early in the
course of the disease in which therapy with DMARDs
can effectively influence the long-term prognosis. It is,
therefore, of great importance that general practitioners and
rheumatologists join in their efforts to diagnose and treat
patients with RA as early as possible.
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Figures (large format)
Figure 1
Progression of joint erosion score (Ratingen) over time in patients treated early vs patients treated late with disease-modifying antirheumatic
drugs (DMARDs). Mean erosion (ERO) scores (± SEM) are shown as percentages of maximum damage score as a function of time since
symptom onset. Regression analysis with adjustment for potential confounders of radiographic progression revealed a significant difference in
the slopes of radiographic damage progression.
Reproduced from: Kyburz D, Gabay C, Michel BA, Finckh A. The long-term impact of early treatment of rheumatoid arthritis on radiographic
progression: a population-based cohort study. Rheumatology (Oxford). 2011;50(6):1106–10, by permission of the British Society of
Rheumatology.
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